AMP.L Regulatory News (AMP)

8 Jun 2006 07:01

Amphion Innovations PLC08 June 2006 Amphion Innovations Names Zaki Hosny as CEO of Partner Company Motif BioSciences 8 June 2006 - Amphion Innovations plc (LSE:AMP - "Amphion"), a leading developerand operator of companies in the life sciences and medical technology sectors,today announced that its partner company, Motif BioSciences, Inc., has namedZaki Hosny deputy chairman and chief executive officer. This appointment,effective from July 1 2006, marks an important milestone in Motif's progress asit advances its programs in the Arabian Gulf region. Mr. Hosny has more than three decades of experience in the pharmaceuticalindustry, with specific expertise in creating and implementing successfulmarketing strategies and product launches as well as ongoing product developmentand sales. In addition, he has considerable international experience, includingwithin the Middle East and Europe, and has extensive experience buildingstrategic relationships with governments and regulators. Mr. Hosny comes to Motif from Merck and Company, Inc., where he most recentlyheld the position of vice president of marketing and operations for Europe, theMiddle East and Africa. In that role, he was responsible for the development ofmarketing strategies for the entire product portfolio of the region. Inprevious positions, Mr. Hosny successfully supervised business units in manyparts of Europe with significant sales and income. Mr. Hosny succeeds Dr. Stephen Cass as CEO of Motif. Dr. Cass, a managingdirector of Amphion, will remain committed to Motif full time for theforeseeable future in the role of vice president for business development. Richard C.E. Morgan, chief executive officer of Amphion Innovations plc andchairman of Motif: "We are delighted to be bringing Zaki into our company at this significantjuncture. Stephen has played a critical role in bringing Motif to the pointwhere we can attract an executive of Zaki's skill and experience. We areindebted to Stephen for his contributions and look forward to his continuinginvolvement in the success of the company. "The Gulf region has been underserved in pharmaceutical and genetic research andMotif is excited to be partnering with leading Gulf countries to help bringstate of the art science and technology to the region. Zaki's experience inmanaging the processes that support pharmaceutical discovery, development andcommercialization will help us advance Motif and its genetic research to thenext level." Mr. Hosny said: "I am excited to be joining Motif and look forward to working closely with theAmphion team in taking the company forward in the region. In the past fewmonths, interest in Motif's programs in the Gulf has sharpened considerably,particularly in relation to what our research can do to advance theunderstanding and, in due course, the treatment of diabetes and otherafflictions which are prevalent in the area." For More Information: Amphion Innovations plc +1 (212) 210-6224Richard Morgan, Chief ExecutiveAaron Kwittken, Media Relations +1 (646) 747-7144 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert Notes to editors: About Amphion Innovations plc Amphion Innovations plc is quoted on AIM market of the London Stock Exchangeunder the symbol AMP. Amphion's business is the formation, financing,management and development of life sciences and technology companies, working inpartnership with corporations, governments, universities and entrepreneursseeking to commercialize their intellectual property. About Motif Biosciences, Inc. Motif BioSciences, Inc. (http://www.motifbio.com) is a population geneticscompany focused on discovering genetic causes of major diseases by interpretingthe wealth of genomic data from Arabian Gulf Region. This information is provided by RNS The company news service from the London Stock Exchange